Ignite Creation Date:
2024-05-06 @ 5:32 PM
Last Modification Date:
2024-10-26 @ 2:31 PM
Study NCT ID:
NCT05346224
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-04-16
First Post:
2022-04-17
Brief Title:
A Study to Evaluate the Efficacy and Safety of HLX11 vs EU-Perjeta in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer
Sponsor:
Shanghai Henlius Biotech
Organization:
Shanghai Henlius Biotech
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-04-25
Start Date Type:
ACTUAL
Primary Completion Date:
2024-11-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-12-30
Completion Date Type:
ESTIMATED
First Submit Date:
2022-04-17
First Submit QC Date:
April 23 2022
Study First Post Date:
2022-04-26
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-04-14
Last Update Post Date:
2024-04-16
Last Update Post Date Type:
ACTUAL